Stocks & ETFs Screener: 200+ results (Biotechnology)
| Symbol | Industry | Market Cap | Fund. Score | Div. Score | Tech. Score | P/E | Return 12m vs S&P 500 |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie |
Biotechnology
Biologics, Immunology, Oncology |
406B | 50.7% | 68.7% | 89.1% | 175 | 23.7% |
| AMGN Amgen |
Biotechnology
Rheumatoid Arthritis, Psoriasis |
181B | 82.4% | 67.9% | 53.6% | 26.0 | 6.19% |
| GILD Gilead Sciences |
Biotechnology
Antivirals, Oncology, Hepatitis |
155B | 83.5% | 65.5% | 88.4% | 19.4 | 29.1% |
| VRTX Vertex |
Biotechnology
Cystic Fibrosis, Sickle Cell, Beta |
109B | 87.4% | - | 20.6% | 30.0 | -17.2% |
| REGN Regeneron |
Biotechnology
Eylea, Dupixent, Libtayo |
78.1B | 79.4% | 14.9% | -8.26% | 17.7 | -9.16% |
| ALNY Alnylam |
Biotechnology
RNAi Therapeutics, Patisiran |
60.0B | 60.3% | - | 86.6% | - | 55.8% |
| ARGX argenx |
Biotechnology
Antibody,Autoimmune,Therapy,FcRn,Ig.. |
57.2B | 71.1% | - | 80.8% | 39.2 | 35.9% |
| HLN Haleon |
Biotechnology
Toothpaste, Vitamins, Pain-Relief |
44.0B | 52.5% | 53.2% | 50.0% | 21.8 | -6.01% |
| INSM Insmed |
Biotechnology
Inhaled Antibiotic, DPP1 |
42.4B | 33.9% | - | 86.4% | - | 140% |
| ONC BeiGene |
Biotechnology
BTK-Inhibitor, Anti-PD-1 |
38.7B | 63.7% | - | 66.5% | 659 | 63.7% |
| NTRA Natera |
Biotechnology
Prenatal Screening, Carrier |
27.7B | 47.3% | - | 68.6% | - | 25.7% |
| 22UA BioNTech SE |
Biotechnology
Cancer Vaccines, mRNA Therapies |
24.9B | 21.7% | 1.0% | -68.0% | - | -31.8% |
| BNTX BioNTech SE |
Biotechnology
Oncology Vaccines,Checkpoint |
24.7B | 17.6% | 1.0% | -56.6% | - | -29.1% |
| BIIB Biogen |
Biotechnology
Multiple Sclerosis Therapies |
24.6B | 71.9% | - | -34.4% | 15.3 | -1.06% |
| UTHR United Therapeutics |
Biotechnology
Treprostinil, Treprostinil |
20.1B | 92.5% | - | 65.1% | 17.7 | 15.4% |
| INCY Incyte |
Biotechnology
JAKAFI, MONJUVI, PEMAZYRE |
19.9B | 90.1% | - | 34.9% | 17.2 | 24.4% |
| GMAB Genmab AS |
Biotechnology
Antibody, Cancer, Lymphoma |
18.8B | 82.2% | - | -2.28% | 13.3 | 31.2% |
| BIM Biomerieux |
Biotechnology
Diagnostic, Instruments, Reagents |
14.7B | 80.4% | 60.4% | 32.0% | 33.9 | -0.87% |
| NBIX Neurocrine |
Biotechnology
Movement, Endocrine |
14.4B | 85.0% | - | 36.3% | 34.6 | -0.05% |
| ROIV Roivant Sciences |
Biotechnology
Antibody, Small-Molecule, Inhaled |
14.1B | 29.4% | - | 81.6% | - | 45.4% |
| EXAS EXACT Sciences |
Biotechnology
Colorectal, Breast, Colon |
13.2B | 46.3% | - | 35.4% | - | 63.9% |
| ASND Ascendis Pharma AS |
Biotechnology
Growth Hormone |
12.6B | 36.0% | - | 77.7% | - | 44.1% |
| BBIO BridgeBio Pharma |
Biotechnology
ATTR Medication, FGFR Inhibitor |
12.5B | 50.7% | - | 83.1% | - | 124% |
| RVMD Revolution |
Biotechnology
RAS Inhibitors, Companion |
12.4B | 25.2% | - | 57.9% | - | 10.4% |
| SMMT Summit Therapeutics |
Biotechnology
Antibody, Immunotherapy, Oncology |
12.3B | 47.2% | - | 53.5% | - | -24.4% |
| ERF Eurofins |
Biotechnology
Testing, Laboratory, Services |
12.1B | 70.5% | 2.77% | 17.9% | 26.0 | 10.4% |
| IONS Ionis |
Biotechnology
Triglyceride, Amyloidosis, SMA |
12.1B | 24.3% | 0.21% | 67.2% | - | 92.2% |
| MDGL Madrigal |
Biotechnology
Rezdiffra, Liver Therapy, MASH |
12.0B | 57.3% | - | 82.1% | - | 42.2% |
| EXEL Exelixis |
Biotechnology
Cabozantinib, Cobimetinib |
11.3B | 93.7% | - | 79.8% | 17.7 | 4.67% |
| BMRN Biomarin |
Biotechnology
Enzyme replacement therapy |
10.4B | 85.4% | - | -69.1% | 20.1 | -24.7% |
| MRNA Moderna |
Biotechnology
Respiratory Vaccines, Latent |
9.75B | 26.0% | - | -86.1% | - | -51.3% |
| HALO Halozyme |
Biotechnology
Enzyme, Cancer, Immunodeficiency |
8.26B | 92.1% | - | 50.9% | 14.8 | 31.9% |
| ABVX Abivax American |
Biotechnology
Obefazimod, Immunoregulatory |
8.19B | 38.7% | - | 75.6% | - | 1,155% |
| ABVX Abivax |
Biotechnology
Drug, Phase3, Ulcerative, Crohns |
8.02B | 39.0% | - | 68.1% | - | 1,026% |
| CYTK Cytokinetics |
Biotechnology
Cardiac Activator, Skeletal |
7.76B | 43.3% | - | 39.9% | - | 16.7% |
| GRFS Grifols |
Biotechnology
Immunoglobulin, Albumin |
7.65B | 67.9% | 40.9% | 15.8% | 13.8 | -11.1% |
| MTSR Metsera, Common |
Biotechnology
Injectable, Oral, Obesity, Peptides |
7.43B | 49.1% | - | 91.2% | - | 250% |
| MRUS Merus BV |
Biotechnology
Bispecific Antibodies, BIZENGRI |
7.28B | 31.2% | - | 91.8% | - | 89.0% |
| NUVL Nuvalent |
Biotechnology
ROS1 Inhibitor, ALK Inhibitor |
6.89B | 25.4% | - | 62.0% | - | -0.81% |
| RYTM Rhythm |
Biotechnology
Setmelanotide, Rare Obesity, MC4R |
6.63B | 43.2% | - | 92.8% | - | 52.1% |
| RGC Regencell |
Biotechnology
Traditional Chinese Medicine |
6.24B | 36.4% | - | 78.6% | - | 7,094% |
| PTCT PTC Therapeutics |
Biotechnology
Translarna, Emflaza, Upstaza |
6.07B | 64.5% | - | 59.4% | 8.93 | 63.5% |
| PCVX Vaxcyte |
Biotechnology
Pneumococcal, Streptococcus |
5.96B | 26.7% | - | -11.6% | - | -53.3% |
| KRYS Krystal Biotech |
Biotechnology
Gene, Therapy, Topical, Wound, Skin |
5.93B | 89.1% | - | 61.0% | 30.7 | -2.38% |
| ARWR Arrowhead |
Biotechnology
Plozasiran, Olpasiran, Fazirsiran |
5.70B | 34.9% | - | 26.5% | - | 92.8% |
| LEGN Legend Biotech |
Biotechnology
CAR-T, Oncology, Myeloma |
5.43B | 32.1% | - | -48.0% | - | -40.9% |
| COGT Cogent Biosciences |
Biotechnology
Kinase Inhibitor, FGFR Inhibitor |
5.33B | 47.8% | - | 64.8% | - | 258% |
| ACLX Arcellx |
Biotechnology
Anitocabtagene Autoleucel |
5.24B | 32.4% | - | 68.4% | - | -9.64% |
| PTGX Protagonist |
Biotechnology
Peptide, Hematology, Inflammation |
5.20B | 64.2% | - | 89.1% | 126 | 68.0% |
| TGTX TG Therapeutics |
Biotechnology
Anti-CD20 Antibody, BTK Inhibitor |
4.92B | 66.2% | - | 37.9% | 11.2 | -17.3% |
| CRSP Crispr Therapeutics |
Biotechnology
Gene-Edited Cell Therapy, CAR T |
4.87B | 27.2% | - | 4.69% | - | -10.7% |
| ALKS Alkermes |
Biotechnology
Schizophrenia, Bipolar, Alcohol |
4.83B | 86.5% | - | 11.2% | 14.6 | -12.7% |
| KYMR Kymera Therapeutics |
Biotechnology
IRAK4, STAT6, TYK2, Protein |
4.65B | 27.4% | - | 59.2% | - | 25.8% |
| APGE Apogee |
Biotechnology
Monoclonal Antibody, Atopic |
4.53B | 35.0% | - | 60.9% | - | 35.4% |
| PRAX Praxis Precision |
Biotechnology
Ulixacaltamide, Vormatrigine |
4.45B | 28.0% | - | 45.9% | - | 104% |
| CELC Celcuity |
Biotechnology
Cancer Test, Therapy Candidate |
4.36B | 24.3% | - | 77.6% | - | 528% |
| NAMS NewAmsterdam |
Biotechnology
Obicetrapib, Ezetimibe, CETP |
4.34B | 33.6% | - | 81.1% | - | 62.9% |
| VKTX Viking Therapeutics |
Biotechnology
VK2809, VK2735, VK5211, VK0214 |
4.27B | 39.5% | - | 41.6% | - | -41.0% |
| BLTE Belite Bio |
Biotechnology
Oral Therapy, Stargardt |
4.21B | 32.9% | - | 83.8% | - | 43.3% |
| IMVT Immunovant |
Biotechnology
Monoclonal Antibodies, Autoimmune |
4.16B | 25.3% | - | 15.2% | - | -24.8% |
| ACAD ACADIA |
Biotechnology
Parkinsons Psychosis Drug, Rett |
4.06B | 85.8% | - | 51.6% | 15.3 | 27.6% |
| CRNX Crinetics |
Biotechnology
Paltusotine, Atumelnant, CRN09682 |
4.05B | 22.7% | - | 37.9% | - | -31.6% |
| INDV Indivior Ordinary |
Biotechnology
Suboxone, Sublocade, Subutex, Opvee |
4.03B | 74.7% | 2.63% | 60.2% | 32.9 | 169% |
| CNTA Centessa |
Biotechnology
Sleep Disorder Drug |
4.02B | 30.3% | - | 70.5% | - | 46.6% |
| LGND Ligand |
Biotechnology
Infectious, Oncology, Nephrology |
3.92B | 55.6% | 0.14% | 82.0% | 87.7 | 48.0% |
| SRRK Scholar Rock |
Biotechnology
Monoclonal Antibodies, Inhibitor |
3.88B | 22.8% | - | 33.8% | - | -4.51% |
| ADMA ADMA Biologics |
Biotechnology
IVIG, Immune Globulin, Hepatitis |
3.70B | 84.7% | - | 38.4% | 18.1 | -28.3% |
| GRAL GRAIL |
Biotechnology
Cancer Screening, Diagnostic Aid |
3.65B | 40.1% | - | 91.5% | - | 374% |
| MIRM Mirum |
Biotechnology
LIVMARLI, Cholbam, Chenodal |
3.55B | 48.4% | - | 91.8% | - | 43.6% |
| MLYS Mineralys |
Biotechnology
Phase II Inhibitor, Oral |
3.51B | 31.0% | - | 73.6% | - | 195% |
| IRON Disc Medicine |
Biotechnology
Porphyria Drug, Anemia Drug |
3.50B | 33.0% | - | 43.6% | - | 28.6% |
| CGON CG Oncology |
Biotechnology
Oncolytic Immunotherapy |
3.42B | 32.2% | - | 19.3% | - | 12.0% |
| CDTX Cidara Therapeutics |
Biotechnology
Antifungal, Antiviral, Oncology |
3.33B | 22.1% | - | 77.7% | - | 951% |
| RARE Ultragenyx |
Biotechnology
Biologic, Gene Therapy, Antibody |
3.19B | 36.4% | - | -48.4% | - | -36.1% |
| VCYT Veracyte |
Biotechnology
Thyroid, Prostate, Bladder |
3.15B | 64.3% | - | 19.8% | 106 | -4.08% |
| KNSA Kiniksa |
Biotechnology
ARCALYST, Vixarelimab, KPL-387 |
3.13B | 68.5% | - | 92.9% | 91.7 | 70.9% |
| TVTX Travere |
Biotechnology
Medication, Tablets, Enzyme |
3.11B | 29.2% | - | 40.1% | - | 70.9% |
| XENE Xenon |
Biotechnology
Kv7 Opener, Phase 3, Epilepsy |
3.09B | 32.9% | - | 16.6% | - | -11.5% |
| DYN Dyne Therapeutics |
Biotechnology
Therapeutics, Muscular Dystrophy |
2.94B | 28.5% | - | 20.7% | - | -35.6% |
| IDYA Ideaya Biosciences |
Biotechnology
Oncology, Kinase, Inhibitor, ADC |
2.90B | 24.9% | - | 58.2% | - | 14.7% |
| CPRX Catalyst |
Biotechnology
Firdapse, Fycompa, Ruzurgi, Agamree |
2.83B | 91.0% | - | 25.1% | 13.5 | -1.59% |
| ARQT Arcutis |
Biotechnology
Topical Cream, Topical Foam, JAK1 |
2.80B | 41.4% | - | 49.6% | - | 145% |
| VRDN Viridian |
Biotechnology
Monoclonal Antibody, Thyroid Eye |
2.77B | 50.3% | - | 31.8% | - | 29.2% |
| DNLI Denali Therapeutics |
Biotechnology
RIPK1 Inhibitor, LRRK2 Inhibitor |
2.56B | 25.5% | - | -60.0% | - | -34.2% |
| AGIO Agios Pharm |
Biotechnology
Mitapivat, Tebapivat, AG-181 |
2.55B | 35.9% | - | -10.4% | - | -60.7% |
| SLNO Soleno Therapeutics |
Biotechnology
Diazoxide, Choline, Tablet, Rare |
2.54B | 41.7% | - | 60.1% | - | -29.4% |
| APLS Apellis |
Biotechnology
Therapeutic, Complement |
2.48B | 76.6% | - | -64.6% | 54.5 | -45.0% |
| RCUS Arcus Biosciences |
Biotechnology
HIF-2a-Inhibitor |
2.47B | 34.0% | - | -16.4% | - | 35.7% |
| ZLAB Zai Lab |
Biotechnology
Oncology, Immunology |
2.46B | 29.7% | - | -41.2% | - | -36.2% |
| EWTX Edgewise |
Biotechnology
Muscle Disorder Therapies |
2.41B | 30.4% | - | 10.4% | - | -36.5% |
| FOLD Amicus Therapeutics |
Biotechnology
Galafold, Pombiliti, Opfolda, Gene |
2.35B | 53.6% | - | -30.5% | - | -11.9% |
| NNNN Anbio |
Biotechnology
Antigen Tests, Immunoassay |
2.32B | 66.8% | - | 85.5% | 858 | 279% |
| RXRX Recursion |
Biotechnology
Drug Discovery Platform |
2.26B | 26.5% | - | -69.7% | - | -37.7% |
| BEAM Beam Therapeutics |
Biotechnology
Base-Editing Therapeutics, Sickle |
2.20B | 26.2% | - | -61.7% | - | -25.4% |
| GLPG Galapagos |
Biotechnology
CAR-T, Oncology, Immunology |
2.17B | 27.1% | - | -15.8% | - | -8.77% |
| GLPG Galapagos |
Biotechnology
Medicine, Oncology, Immunology |
2.16B | 40.1% | - | -2.29% | - | 0.57% |
| GPCR Structure |
Biotechnology
GSBR-1290, ACCG-2671, ANPA-0073 |
2.08B | 30.2% | - | 25.7% | - | -9.61% |
| IBRX Immunitybio |
Biotechnology
Immunotherapy, Vaccine, Cytokine |
2.05B | 66.8% | - | -73.8% | - | -63.0% |
| AUPH Aurinia |
Biotechnology
Immunosuppressant, Lupus |
2.02B | 94.3% | - | 60.5% | 27.4 | 61.3% |
| VCEL Vericel Ord |
Biotechnology
Cartilage, Skin, Burn, Autologous |
2.02B | 60.3% | - | 0.39% | 153 | -39.5% |
| SION Sionna |
Biotechnology
Galicaftor, Navocaftor, SION-109 |
1.95B | 37.1% | - | 90.8% | - | 121% |
| MESO Mesoblast |
Biotechnology
Stem-Cell Therapy, Inflammation |
1.94B | 31.7% | - | 38.7% | - | 24.8% |
| ZBIO Zenas BioPharma |
Biotechnology
Bifunctional Monoclonal Antibody |
1.91B | 31.4% | - | 83.3% | 2.61 | 184% |
| QURE Uniqure |
Biotechnology
Gene Therapy, Hemophilia Treatment |
1.89B | 35.4% | - | 18.2% | - | 316% |
| SRPT Sarepta |
Biotechnology
RNA Therapeutics, Duchenne |
1.83B | 29.0% | - | -77.4% | - | -86.2% |
| SYRE Spyre Therapeutics |
Biotechnology
Monoclonal Antibodies |
1.82B | 30.4% | - | -33.1% | - | -21.9% |
| VERA Vera Therapeutics |
Biotechnology
Atacicept, Mab, Dual-Inhibitor |
1.81B | 22.9% | 3.50% | 13.4% | - | -46.1% |
| ZYME Zymeworks Common |
Biotechnology
Zanidatamab, Bispecific Antibody |
1.80B | 22.3% | - | 65.2% | - | 51.5% |
| IMCR Immunocore Holdings |
Biotechnology
Oncology Immunotherapy |
1.79B | 43.2% | - | 2.02% | - | 7.50% |
| JANX Janux Therapeutics |
Biotechnology
JANX007, JANX008, TRACTr, TRACIr |
1.76B | 28.4% | - | 4.30% | - | -47.2% |
| ALVO Alvotech |
Biotechnology
Biosimilar, Autoimmune, Oncology |
1.72B | 38.5% | - | -45.1% | 24.0 | -61.6% |
| NUVB Nuvation Bio |
Biotechnology
Oncology Pipeline Drug Candidates |
1.61B | 34.1% | - | 58.7% | - | 117% |
| IMNM Immunome |
Biotechnology
Antibody, Oncology, Bispecific |
1.61B | 41.4% | - | 61.7% | - | 48.9% |
| STOK Stoke Therapeutics |
Biotechnology
STK-002,Zorevunersen,ASOs,TANGO,Gen.. |
1.60B | 73.2% | - | 64.8% | 41.1 | 123% |
| TWST Twist Bioscience |
Biotechnology
Synthetic DNA, Gene Fragments |
1.59B | 35.2% | - | -35.8% | - | -44.9% |
| CLDX Celldex |
Biotechnology
Monoclonal Antibody, Bispecific |
1.58B | 37.7% | - | -19.8% | - | -17.5% |
| PHVS Pharvaris BV |
Biotechnology
Bradykinin, Antagonist |
1.56B | 30.7% | - | 66.2% | - | -6.11% |
| MNKD MannKind |
Biotechnology
Inhaled Insulin, Insulin Delivery |
1.56B | 64.2% | - | -7.57% | 50.7 | -33.0% |
| DNTH Dianthus |
Biotechnology
Monoclonal Antibody, DNTH103 |
1.52B | 28.1% | - | 44.4% | - | 58.3% |
| BCRX BioCryst |
Biotechnology
Antiviral Injection, Oral HAE |
1.47B | 72.4% | - | -38.7% | - | -14.1% |
| MEDCL Medincell |
Biotechnology
Schizophrenia, Postoperative Pain |
1.46B | 54.7% | - | 80.2% | - | 43.0% |
| SNDX Syndax |
Biotechnology
Menin Inhibitor, CSF-1R Antibody |
1.45B | 40.0% | - | -17.6% | - | -6.62% |
| ARDX Ardelyx |
Biotechnology
IBS-C Therapy, Phosphate |
1.42B | 30.0% | - | 43.2% | - | -7.52% |
| ATAI ATAI Life Sciences |
Biotechnology
Psychedelic, Intranasal, Oral |
1.38B | 37.1% | - | 37.4% | - | 103% |
| PGEN Precigen |
Biotechnology
UltraCAR-T, AdenoVerse, PRGN-3005 |
1.36B | 37.7% | - | 56.9% | - | 274% |
| TNGX Tango Therapeutics |
Biotechnology
PRMT5 Inhibitor, Glioblastoma |
1.35B | 32.7% | - | 40.2% | - | 136% |
| ORKA Oruka Therapeutics |
Biotechnology
Monoclonal Antibody |
1.33B | 29.6% | 1.0% | 47.8% | - | 41.8% |
| BTX BlackRock |
Biotechnology
Technology, Private, Equity |
1.32B | 34.8% | 87.9% | 10.5% | 51.8 | -18.8% |
| DVAX Dynavax |
Biotechnology
Hepatitis Vaccine, Adjuvant |
1.31B | 45.5% | - | -27.7% | - | -19.8% |
| BHVN Biohaven |
Biotechnology
Troriluzole, Taldefgrobep |
1.29B | 36.5% | - | -54.4% | - | -80.8% |
| NRIX Nurix Therapeutics |
Biotechnology
BTK Degrader, IRAK4 Degrader |
1.29B | 30.8% | - | -15.9% | - | -31.2% |
| UPB Upstream Bio |
Biotechnology
Verekitug, Asthma, Rhinosinusitis |
1.26B | 38.0% | - | 55.4% | - | 22.5% |
| IMTX Immatics |
Biotechnology
TCR-Engineered Cell Therapy, TCR |
1.24B | 23.7% | - | 13.4% | - | 20.4% |
| ORIC Oric |
Biotechnology
ORIC-114, ORIC-944, ORIC-533 |
1.18B | 33.8% | - | 57.4% | - | 5.46% |
| URGN UroGen Pharma |
Biotechnology
Jelmyto, UGN-102, UGN-103 |
1.16B | 46.5% | - | 67.4% | - | 85.7% |
| TSHA Taysha Gene |
Biotechnology
Gene, Therapy, AAV, CNS, Monogenic |
1.15B | 36.4% | - | 51.5% | - | 29.9% |
| NVAX Novavax |
Biotechnology
Vaccine, Adjuvant, Nanoparticle |
1.15B | 40.5% | - | -53.7% | 3.51 | -37.8% |
| PHARM Pharming |
Biotechnology
RUCONEST, Joenja, OTL-105 |
1.15B | 69.7% | - | 46.9% | - | 74.7% |
| XNCR Xencor |
Biotechnology
Engineered Monoclonal Antibodies |
1.13B | 18.3% | - | -65.7% | - | -45.5% |
| CVAC CureVac |
Biotechnology
MRNA Vaccines, Oncology Therapies |
1.13B | 85.0% | - | 2.51% | 5.08 | 62.7% |
| RLAY Relay Therapeutics |
Biotechnology
PI3Ka Inhibitor, Estrogen |
1.12B | 46.9% | - | -32.1% | - | 24.8% |
| PVLA Palvella |
Biotechnology
Topical Rapamycin Gel, Microcystic |
1.11B | 24.8% | - | 32.4% | - | 401% |
| OCS Oculis Holding |
Biotechnology
OCS-01, OCS-02, OCS-05 |
1.11B | 29.4% | - | 60.4% | - | 16.7% |
| MBX MBX Biosciences |
Biotechnology
Hypoparathyroidism, Hypoglycemia |
1.11B | 31.6% | - | 51.5% | 3.23 | 25.1% |
| CSTL Castle Biosciences |
Biotechnology
Melanoma, Squamous, Uveal |
1.11B | 53.5% | - | 22.6% | - | 15.0% |
| ABCL Abcellera Biologics |
Biotechnology
Antibody, Metabolic, Autoimmune |
1.10B | 19.3% | - | -24.3% | - | 6.58% |
| MDXG MiMedx |
Biotechnology
Placental Allografts, Wound Care |
1.10B | 83.7% | - | 13.6% | 27.3 | -33.4% |
| MNMD Mind Medicine |
Biotechnology
MM120, MM402, Anxiety, ADHD, Autism |
1.06B | 29.0% | - | 66.5% | - | 25.7% |
| KOD Kodiak Sciences |
Biotechnology
Anti-VEGF, Biopolymer Conjugate |
1.04B | 44.4% | - | 46.3% | - | 189% |
| NBTX Nanobiotix |
Biotechnology
Nanoparticles, Radiotherapy |
1.01B | 45.8% | - | 76.0% | - | 436% |
| NANO Nanobiotix S.A |
Biotechnology
Nanoparticle, Radiotherapy |
1.01B | 41.7% | - | 74.0% | - | 390% |
| NTLA Intellia |
Biotechnology
In-Vivo CRISPR, CAR-T, NK Cell |
1.01B | 34.1% | - | -64.3% | - | -50.3% |
| BCAX Bicara |
Biotechnology
Ficerafusp Alfa, Bifunctional |
988M | 29.8% | - | -14.7% | 3.35 | -11.5% |
| OPK Opko Health |
Biotechnology
Diagnostics, Laboratory-Testing |
983M | 20.6% | - | -36.6% | - | -27.0% |
| IOVA Iovance |
Biotechnology
Amtagvi, Proleukin, Lifileucel |
981M | 42.7% | - | -80.6% | - | -78.4% |
| KURA Kura Oncology |
Biotechnology
Menin Inhibitor, Farnesyl |
975M | 54.0% | - | -23.2% | - | -8.71% |
| SANA Sana Biotechnology |
Biotechnology
Allogeneic Islet Therapy, CAR-T |
975M | 33.9% | - | -1.75% | - | 18.8% |
| ANAB AnaptysBio |
Biotechnology
Antibody, Autoimmune |
936M | 24.6% | - | 46.5% | - | 47.2% |
| GLUE Monte Rosa |
Biotechnology
MRT-2359, MRT-6160, MRT-8102, CDK2 |
935M | 71.6% | - | 24.6% | 44.9 | 50.6% |
| RZLT Rezolute |
Biotechnology
Antibody, Hyperinsulinism |
915M | 35.0% | - | 70.8% | - | 81.2% |
| DAWN Day One |
Biotechnology
Tovorafenib, DAY301, VRK1 Inhibitor |
909M | 31.3% | - | -70.9% | - | -43.1% |
| MLTX MoonLake |
Biotechnology
Nanobody, IL-17A, IL-17F |
905M | 25.8% | - | 9.04% | - | -79.1% |
| SVRA Savara |
Biotechnology
Molgramostim, Proteinosis |
875M | 21.8% | - | 72.0% | - | 29.2% |
| ABUS Arbutus Biopharma |
Biotechnology
RNAi Therapeutic, PD-L1 Inhibitor |
874M | 30.8% | - | 54.9% | - | 12.9% |
| GHRS GH Research |
Biotechnology
Mebufotenin, Depression |
868M | 27.0% | - | 33.0% | - | 37.8% |
| LENZ LENZ Therapeutics |
Biotechnology
Ophthalmic, Presbyopia, Clinical |
867M | 39.4% | 1.0% | 19.4% | - | -26.2% |
| CMPX Compass |
Biotechnology
Tovecimig, CTX-471, CTX-8371 |
859M | 28.3% | - | 35.5% | - | 191% |
| AVBP ArriVent |
Biotechnology
Firmonertinib, ARR-217, ARR-002 |
840M | 40.1% | - | -17.8% | - | -33.7% |
| TYRA Tyra Biosciences |
Biotechnology
Precision Medicine Platform, FGFR |
840M | 28.3% | - | 49.7% | - | 16.9% |
| RIGL Rigel |
Biotechnology
Kinase, Inhibitor |
839M | 92.0% | - | 67.4% | 7.47 | 58.7% |
| SPRY ARS |
Biotechnology
Epinephrine, Nasal Spray |
831M | 26.6% | - | -5.21% | - | -50.4% |
| CDNA CareDx |
Biotechnology
AlloSure, AlloMap, AlloSeq |
820M | 52.7% | - | -25.6% | 12.5 | -36.2% |
| IVA Inventiva S.A |
Biotechnology
Lanifibranor, Odiparcil, TGF-Beta |
794M | 43.3% | - | 13.5% | - | 27.5% |
| ORGO Organogenesis |
Biotechnology
Wound Care, Surgical Matrix |
788M | 33.3% | - | 46.9% | - | 24.0% |
| VIR Vir Biotechnology |
Biotechnology
HDV, RSV, HPV, Coronavirus, TCE |
783M | 29.9% | - | -80.2% | - | -31.6% |
| RAPT RAPT Therapeutics |
Biotechnology
CCR4 Antagonist, Inflammation |
770M | 29.2% | - | -25.9% | - | 171% |
| ALMS Alumis |
Biotechnology
TYK2 Inhibitor, Psoriasis, Lupus |
762M | 50.9% | - | -77.1% | - | -30.6% |
| VLA Valneva SE |
Biotechnology
Japanese Encephalitis, Cholera |
745M | 21.5% | - | -6.62% | - | 67.6% |
| GERN Geron |
Biotechnology
Telomerase Inhibitor |
737M | 28.8% | - | -65.9% | - | -75.5% |
| ERAS Erasca |
Biotechnology
Naporafenib, ERAS-0015, ERAS-4001 |
721M | 33.5% | - | -41.8% | - | -5.23% |
| ATXS Astria Therapeutics |
Biotechnology
Monoclonal, Antibody, Plasma |
711M | 33.9% | - | 18.7% | - | 12.1% |
| REPL Replimune |
Biotechnology
Oncolytic Immunotherapy, RP1, RP2 |
705M | 28.0% | - | -74.5% | - | -37.9% |
| ESPR Esperion |
Biotechnology
Cholesterol-Lowering Tablets |
702M | 53.4% | - | -28.5% | - | 7.35% |
| LXEO Lexeo |
Biotechnology
Gene Therapy, Cardiomyopathy |
692M | 34.7% | - | -10.8% | - | 12.3% |
| KALV Kalvista |
Biotechnology
Plasma Kallikrein Inhibitors, Oral |
688M | 37.6% | - | 61.3% | - | 16.5% |
| MGTX MeiraGTx Holdings |
Biotechnology
Gene Therapies, Retinal Diseases |
666M | 32.6% | - | 24.5% | - | 5.57% |
| CRVS Corvus |
Biotechnology
Kinase Inhibitor, Adenosine |
665M | 32.1% | - | 54.9% | - | -14.0% |
| CTMX CytomX Therapeutics |
Biotechnology
Antibody-Drug Conjugate, T-Cell |
657M | 60.1% | - | 51.1% | 12.9 | 262% |
| ANNX Annexon |
Biotechnology
Antibody, Fragment |
636M | 34.3% | - | -39.0% | - | -25.0% |
| PROK ProKidney |
Biotechnology
Cell Therapy, Renal Cells |
629M | 42.5% | - | -25.0% | - | 7.20% |
| GOSS Gossamer Bio |
Biotechnology
Seralutinib, GB002, PAH Therapy |
627M | 34.5% | - | -5.21% | - | 292% |
| VSTM Verastem |
Biotechnology
Avutometinib, Defactinib |
611M | 39.6% | - | 48.3% | - | 129% |
| PRME Prime Medicine |
Biotechnology
Gene Editing, Prime Editing |
608M | 40.5% | - | -31.7% | - | -2.35% |
| MYGN Myriad Genetics |
Biotechnology
Hereditary Cancer, Companion |
600M | 35.5% | 0.08% | -77.1% | - | -57.9% |
| RGNX Regenxbio |
Biotechnology
Gene,Therapy,AAV,Platform,Pipeline |
589M | 22.3% | - | -21.1% | - | 10.3% |
| FDMT 4D Molecular |
Biotechnology
Ophthalmology, Cystic-Fibrosis |
587M | 25.1% | - | -20.5% | - | 27.4% |
| IVVD Invivyd |
Biotechnology
Antibody, Monoclonal, Covid |
583M | 39.6% | - | 24.1% | - | 234% |
| OLMA Olema |
Biotechnology
Palazestrant, OP-3136, KAT6 |
577M | 32.2% | - | 58.1% | - | 133% |
| ASMB Assembly |
Biotechnology
Antiviral, Small-Molecule |
575M | 34.4% | - | 57.6% | - | 133% |
| PRTA Prothena |
Biotechnology
Neurodegeneration, Antibody |
564M | 25.4% | - | -73.0% | - | -37.8% |